<?xml version="1.0" encoding="UTF-8"?>
<p id="Par31">We demonstrated superior therapeutic efficacy and enhancement of NK cell and T cell activation and proliferation when the partially NS1 deleted (116) influenza virus was armed with IL-15
 <sup>
  <xref ref-type="bibr" rid="CR94">94</xref>
 </sup> (Fig. 
 <xref rid="Fig3" ref-type="fig">3b</xref>) in murine models. Subsequently, Penghui et al. were able to show anti-cancer activity of an NS1-deleted influenza A virus armed with GM-CSF in a human Hep-G2 liver cancer cell line xenograft model
 <sup>
  <xref ref-type="bibr" rid="CR95">95</xref>
 </sup>. Hamilton et al. expressed a recombinant humanized cytotoxic T-lymphocyte-associated protein 4 (CTLA4) immune checkpoint inhibiting antibody from two different RNA fragments of the influenza A virus genome in order to enhance its anti-cancer effectiveness in a murine B16 melanoma model
 <sup>
  <xref ref-type="bibr" rid="CR96">96</xref>
 </sup>.
</p>
